Effects of pyrrolidine dithiocarbamate on antioxidant enzymes in cardiomyopathy induced by adriamycin in rats

Cardiology

Volumn 111, Issue 2, 2008, Pages 119-125

  Mingyan, E ^a   Hongli, Li ^b   Shufeng, Li ^a   Bo, Yu ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Adriamycin; Antioxygenation capability, total; Glutathione peroxidase; Pyrrolidine dithiocarbamate; Superoxide dismutase

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; DOXORUBICIN; GLUTATHIONE PEROXIDASE; LIPID PEROXIDE; MANGANESE SUPEROXIDE DISMUTASE; MESSENGER RNA; PYRROLIDINE DITHIOCARBAMATE; SUPEROXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; ELECTRON MICROSCOPY; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE EXPRESSION; HEART MUSCLE; HISTOPATHOLOGY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; WISTAR RAT;

ANIMALS; ANTIOXIDANTS; BIOPSY, NEEDLE; CARDIOMYOPATHIES; DISEASE MODELS, ANIMAL; DOXORUBICIN; ENZYME ACTIVATION; GLUTATHIONE PEROXIDASE; IMMUNOHISTOCHEMISTRY; MALE; MYOCARDIUM; PYRROLIDINES; RANDOM ALLOCATION; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; SUPEROXIDE DISMUTASE; THIOCARBAMATES;

EID: 50849097517     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000119699     Document Type: Article

References (20)

1. Ahn SH, Han KH, Park JY, et al: Treatment outcome of transcatheter arterial chemoin-fusion according to anticancer agents and prognostic factors in patients with advanced hepatocellular carcinoma. Yonsei Med J 2004;45:847-858.
2. Laufman LR, Spiridonidis CH, Jones JJ, et al: Phase I study of doxil and vinorelbine in patients with advanced malignancies. Cancer Invest 2004;22:344-352.
3. Jones RL, Berry GJ, Rubens RD, et al: Clinical and pathological absence of cardiotoxicity after liposomal doxorubicin. Lancet Oncol 2004;5:575-577.
4. Buzdar AU, Marcus C, Smith TL, Blumenschein GR: Early and delayed clinical cardiotoxicity of doxorubicin. Cancer 1985;55:2761-2765.
5. Zhou S, Palmeira CM, Wallace KB: Doxorubicin-induced persistent oxidative stress to cardiac myocytes. Toxicol Lett 2001;121:151-157.
6. Koutinos G, Stathopoulos GP, Dontas I, et al: The effect of doxorubicin and its analogue mitoxantrone on cardiac muscle and on serum lipids: an experimental study. Anticancer Res 2002;22:815-820.
7. Mukherjee S, Banerjee SK, Maulik M, Dinda AK, Talwar KK, Maulik SK: Protection against acute adriamycin-induced cardiotoxicity by garlic: role of endogenous antioxidants and inhibition of TNF-alpha expression. BMC Pharmacol 2003;3:16.
8. Mohamed HE, Asker ME, Ali SI, Fattah TM: Protection against doxorubicin cardiomyopathy in rats: role of phosphodiesterase inhibitors type 4. Pharm Pharmacol 2004;56:757-768.
9. Dudnakova TV, Lakomkin VL, Tsyplenkova VG, Shekhonin BV, Shirinsky VP, Kapelko VI: Alterations in myocardial cytoskeletal and regulatory protein expression following a single doxorubicin injection. J Cardiovasc Pharmacol 2003;41:788-794.
10. Vitelli M, Filippelli A, Rinaldi B, et al: Effects of docosahexaenoic acid on [Ca(2+)](i) increase induced by doxorubicin in ventricular rat cardiomyocytes. Life Sci 2002;71:1905-1916.
11. Zhou S, Heller LJ, Wallace KB: Interference with calcium-dependent mitochondrial bioenergetics in cardiac myocytes isolated from doxorubicin-treated rats. Toxicol Appl Pharmacol 2001;175:60-67.
12. Liu X, Chen Z, Chua CC, et al: Melatonin as an effective protector against doxorubicin-induced cardiotoxicity. Am J Physiol Heart Circ Physiol 2002;283:H254-H263.
13. Nazeyrollas P, Prevost A, Baccard N, Manot L, Devillier P, Millart H: Effects of amifostine on perfused isolated rat heart and on acute doxorubicin-induced cardiotoxicity. Cancer Chemother Pharmacol 1999;43:227-232.
14. Muller DN, Dechend R, Mervaala E, et al: NF-kB inhibition ameliorates angiotensin II-induced inflammatory damage in rats. Hypertension 2000;35:193-201.
15. Beswick RA, Zhang H, Marable D, Catravas JD, Hill WD, Webb RC: Long-term antioxidant administration attenuates mineralocorticoid hypertension and renal inflammatory response. Hypertension 2001;37:781-786.
16. Schreck R, Meier B, Männel DN, et al: Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells. J Exp Med 1992;175:1181-1194.
17. Hongli L, Hongyue G, Baogui S: Protective effects of pyrrolidine dithiocarbamate on myocardium apoptosis induced by adriamycin in rats. Int J Cardiol 2007;114:159-165.
18. Herman EH, Ferrans VJ, Myers CE, Van Vleet JF: Comparison of the effectiveness of (+/-)-1,2 bis (3.5-dioxopiperazinyl-1-yl) propane (ICRF-187) and N-acetylcysteine in preventing chronic doxorubicin cardio toxicity in beagles. Cancer Res 1985;45:276-281.
19. Zhou S, Palmeira CM, Wallace KB: Doxorubicin-induced persistent oxidative stress to cardiac myocytes. Toxicol Lett 2001;121:151-157.
20. Xu MF, Tang PL, Qian ZM, Ashraf M: Effects by doxorubicin on the myocardium are mediated by oxygen free radicals. Life Sci 2001;68:889-901.